Ternary Therapeutics

Executive Summary

Ternary Therapeutics is a London-based startup founded in 2022 that leverages machine learning and molecular dynamics simulations to revolutionize molecular glue discovery. By combining state-of-the-art AI-augmented drug discovery techniques, the company aims to identify novel small molecules that induce protein-protein interactions, a challenging but promising therapeutic modality. As a private early-stage company, Ternary Therapeutics has not disclosed funding or valuation, but its innovative platform addresses a critical need in targeted protein degradation and beyond. The company is headquartered in Cambridge, UK, a hub for biotech innovation, and currently operates at a preclinical stage with no disclosed pipelines. Given the growing interest in molecular glues and AI-driven drug discovery, Ternary Therapeutics has the potential to become a key player, though it remains early and unvalidated by clinical data.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• H1 2027Lead Optimization Data for First Molecular Glue Program50% success
• Q2 2027Partnership with Pharma or CDMO for Co-Development40% success